Vis enkel innførsel

dc.contributor.authorSelli, Anders Lund
dc.contributor.authorGhasemi, Mohammadreza
dc.contributor.authorWatters, Taylor
dc.contributor.authorBurton, Francis
dc.contributor.authorSmith, Godfrey L
dc.contributor.authorDietrichs, Erik Sveberg
dc.date.accessioned2023-11-14T08:40:36Z
dc.date.available2023-11-14T08:40:36Z
dc.date.issued2023-10-25
dc.description.abstractBackground Accidental hypothermia, recognized by core temperature below 35 °C, is a lethal condition with a mortality rate up to 25%. Hypothermia-induced cardiac dysfunction causing increased total peripheral resistance and reduced cardiac output contributes to the high mortality rate in this patient group. Recent studies, in vivo and in vitro, have suggested levosimendan, milrinone and isoprenaline as inotropic treatment strategies in this patient group. However, these drugs may pose increased risk of ventricular arrhythmias during hypothermia. Our aim was therefore to describe the efects of levosimendan, milrinone and isoprenaline on the action potential in human cardiomyocytes during hypothermia.<p> <p>Methods Using an experimental in vitro-design, levosimendan, milrinone and isoprenaline were incubated with iCell2 hiPSC-derived cardiomyocytes and cellular action potential waveforms and contraction were recorded from monolayers of cultured cells. Experiments were conducted at temperatures from 37 °C down to 26 °C. Oneway repeated measures ANOVA was performed to evaluate diferences from baseline recordings and one-way ANOVA was performed to evaluate diferences between drugs, untreated control and between drug concentrations at the specifc temperatures. <p>Results Milrinone and isoprenaline both signifcantly increases action potential triangulation during hypothermia, and thereby the risk of ventricular arrhythmias. Levosimendan, however, does not increase triangulation and the contractile properties also remain preserved during hypothermia down to 26 °C. <p>Conclusions Levosimendan remains a promising candidate drug for inotropic treatment of hypothermic patients as it possesses ability to treat hypothermia-induced cardiac dysfunction and no increased risk of ventricular arrhythmias is detected. Milrinone and isoprenaline, on the other hand, appears more dangerous in the hypothermic setting.en_US
dc.identifier.citationSelli AL, Ghasemi, Watters, Burton F, Smith GL, Dietrichs ES. Proarrhythmic changes in human cardiomyocytes during hypothermia by milrinone and isoprenaline, but not levosimendan: an experimental in vitro study. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine. 2023;31(1)en_US
dc.identifier.cristinIDFRIDAID 2188660
dc.identifier.doi10.1186/s13049-023-01134-5
dc.identifier.issn1757-7241
dc.identifier.urihttps://hdl.handle.net/10037/31748
dc.language.isoengen_US
dc.publisherBMCen_US
dc.relation.journalScandinavian Journal of Trauma, Resuscitation and Emergency Medicine
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2023 The Author(s)en_US
dc.rights.urihttps://creativecommons.org/licenses/by/4.0en_US
dc.rightsAttribution 4.0 International (CC BY 4.0)en_US
dc.titleProarrhythmic changes in human cardiomyocytes during hypothermia by milrinone and isoprenaline, but not levosimendan: an experimental in vitro studyen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution 4.0 International (CC BY 4.0)
Med mindre det står noe annet, er denne innførselens lisens beskrevet som Attribution 4.0 International (CC BY 4.0)